

APPLICANT FACSIMILE OF FORM PTO-1449
 REV 7-80

 U.S. DEPARTMENT OF
 COMMERCE
 PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

MXI-026DVCN2

SERIAL NO.

09/735,173

 LIST OF PUBLICATIONS CITED BY APPLICANT
 (Use several sheets if necessary)

APPLICANT

Ball, Edward D. and Fanger, Michael W.

FILING DATE

December 12, 2000

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CY	AA	4,676,980	06/87	Segal et al.	424	85	
CY	AB	4,954,617	09/90	Fanger et al.	530	387	
CY	AC	5,109,115	04/92	Cuttitta et al.	530	387.9	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
CY	AD	WO 88/00052	01/88	PCT			
CY	AE	WO 91/00360	01/91	PCT			

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

CY	AF	Anderson, C.L. et al. "Monoclonal Antibodies to Fc Receptors for IgG on Human Mononuclear Phagocytes", <i>The Journal of Biological Chemistry</i> 261(27):12856-12864 (1986);
	AG	Eisenthal, A. and Rosenberg, S.A. "The Effect of Various Cytokines on the In Vitro Induction of Antibody-Dependent Cellular Cytotoxicity in Murine Cells", <i>The American Association of Immunologists</i> 142(7):2307-2313(1989);
	AH	Karpovsky, B. et al. "Production of Targeted-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fcγ Receptor Antibodies", <i>J. Exp. Med.</i> 160:1686-1701 (1984);
	AI	Link, B.K. and Weiner, G.J. "Production and Characterization of a Bispecific IgG Capable of Inducing T-Cell-Mediated Lysis of Malignant B Cells", <i>Blood</i> 81(12):3343-3349 (1993);
	AJ	Mokotoff, M. et al. "Synthesis and Biological Evaluation of Novel Potent Antagonists of the Bombesin/Gastrin Releasing Peptide Receptor", <i>J. Med. Chem.</i> 35:4696-4703 (1992);
	AK	Moody, T.W. and Cuttitta, F. "Growth Factor and Peptide Receptors in Small Cell Lung Cancer", <i>Life Sciences</i> 52:1161-1173 (1993);
	AL	Pan, L. et al. "Regulation of the Steady State Level of FcγRI mRNA by IFN-γ and Dexamethasone in Human Monocytes, Neutrophils, and U-937 Cells", <i>The Journal of Immunology</i> 145:267-275 (1990);
	AM	Shen, L. et al. "Heteroantibody-Mediated Cytotoxicity: Antibody to the High Affinity Fc Receptor for IgG Mediates Cytotoxicity by Human Monocytes that is Enhanced by Interferon-γ and is not Blocked by Human IgG", <i>The Journal of Immunology</i> 137(11):3378-3382 (1986);
	AN	Thomas et al. "Antitumoral Activity of Bombesin Analogues on Small Cell Lung Cancer Xenografts: Relationship with Bombesin Receptor Expression", <i>Cancer Research</i> 52:4872-4877 (1992);
	AO	Trail, P.A. et al. "Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates", <i>Science</i> 261:212-215 (1993);
	AP	Vallera D. A., "Immunotoxins: Will Their Clinical Promise Be Fulfilled?", <i>Blood</i> 83(2):309-317 (1994);
	AQ	Weiner et al., "Binding and Cytotoxicity Characteristics of the Bispecific Murine Monoclonal Antibody 2B1", <i>The Journal of Immunology</i> 151(5):2877-2886 (1993).

Examiner

Chris G. M. Y.

Date Considered

5/15/02

*EXAMINER

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 OIPE
 MAR 19 2001
 PATENT & TRADEMARK OFFICE

 RECEIVED
 MAR 2 12 01
 RECEPTION CENTER